List of Arcapta Neohaler drug patents
Arcapta Neohaler is owned by Novartis.
Arcapta Neohaler contains Indacaterol Maleate.
Arcapta Neohaler has a total of 2 drug patents out of which 0 drug patents have expired.
Arcapta Neohaler was authorised for market use on 01 July, 2011.
Arcapta Neohaler is available in powder;inhalation dosage forms.
Arcapta Neohaler can be used as the long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.
The generics of Arcapta Neohaler are possible to be released after 11 October, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(1 year, 10 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(5 years from now) | |
Drugs and Companies using INDACATEROL MALEATE ingredient
Market Authorisation Date: 01 July, 2011
Treatment: The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema
Dosage: POWDER;INHALATION
ARCAPTA NEOHALER family patents
2
Japan
2
European Union
1
Israel
1
South Africa
1
Denmark
1
Austria
1
Mexico
1
Australia
1
Hong Kong
1
Slovenia
1
Russia
1
Morocco
1
Norway
1
Germany
1
United States
1
Argentina
1
Brazil
1
Portugal
1
Cyprus
1
Malaysia
1
Spain
1
Peru
1
Korea, Republic of
1
Poland
1
Taiwan, Province of China
1
United Kingdom
1
China
1
Ecuador
1
Canada
1
Tunisia
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic